fludarabine sandoz 50 mg2ml concentrate for solution for injection or infusion
sandoz products malaysia sdn. bhd. - fludarabine phosphate -
fludarabine phosphate 50 milligram pdr for soln inj/inf
bayer limited - fludarabine phosphate - pdr for soln inj/inf - 50 milligram
hospira fludarabine phosphate for injection usp 50 mg/vial
hospira australia pty ltd - fludarabine phosphate, quantity: 50 mg - injection, intravenous infusion - excipient ingredients: sodium hydroxide; mannitol - fludarabine phosphate for injection usp is indicated for second line therapy in patients with chronic lymphocytic leukemia (cll) and low-grade non-hodgkin's lymphoma (lg-nhl) who have failed other conventional therapies.
fludarabine phosphate 50 mg/vial for injection
hospira australia pty ltd - fludarabine phosphate -
fludarabine actavis
teva pharma (new zealand) limited - fludarabine phosphate 50mg - powder for injection - 50 mg - active: fludarabine phosphate 50mg excipient: mannitol sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia.
fludarabine teva ® 25mg/ml
salomon,levin & elstein ltd - fludarabine phosphate 50 mg / 2 ml - concentrate for solution for injection / infusion - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludarabine teva is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.
fludarabine ebewe
sandoz pty ltd - fludarabine phosphate -
fludarabine phosphate actavis
actavis group ptc ehf - fludarabine phosphate - lyophilisate for solution for injection - 50 milligram
fludara oral fludarabine phosphate 10mg tablet blister pack
sanofi-aventis australia pty ltd - fludarabine phosphate, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; purified talc; titanium dioxide; iron oxide yellow; iron oxide red - indicated for use as second-line tharapy in patients with chronic lymphocytic leukaemia (cll). indications as at 6 april 2004: for the treatment of b-cell chronic lymphocytic leukaemia.
fludarabine phosphate 50mg/2ml concentrate for solution for injection vials
teva uk ltd - fludarabine phosphate - solution for injection - 25mg/1ml